Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BCL11A
REST API REST API
Homo sapiens
BCL11A is differentially expressed in 333 experiments: 161 organism parts: bone marrow, brain, ... (159 more);, 213 disease states: normal, control, ... (211 more);, 140 cell types 512 cell lines 45 compound treatments and 80 other conditions.
Synonyms CTIP1, EVI9, BCL11A-XL, HBFQTL5, ZNF856, BCL11A-S, BCL11A-L
Orthologs Q17QR0_BOVIN (Bos taurus)   D3ZSY3_RAT (Rattus norvegicus)   bcl11ab (Danio rerio)   BCL11A (Gallus gallus)   ENSCING00000002911 (Ciona intestinalis)   Bcl11a (Mus musculus)   bcl11aa (Danio rerio)   CG9650 (Drosophila melanogaster)   bcl11a (Xenopus laevis)   BCL11A (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, cytoplasm, intracellular, negative regulation of axon extension, regulation of dendrite development, transcription corepressor activity, metal ion binding, nucleic acid binding, hemopoiesis, positive regulation of transcription from RNA polymerase II promoter, nucleus, protein heterodimerization activity, nuclear body, protein homodimerization activity, negative regulation of gene expression, zinc ion binding, B cell differentiation, positive regulation of neuron projection development, negative regulation of neuron projection development, negative regulation of collateral sprouting, T cell differentiation, protein sumoylation, negative regulation of protein homooligomerization, positive regulation of collateral sprouting, negative regulation of dendrite development
UniProt Accession Q9H165, Q53TE8, Q53TS1, D6W5D9, D9YZV9, E9PEP4, B4DT16, F5H2Y4
Gene-Disease Assocation FETAL HEMOGLOBIN QUANTITATIVE TRAIT LOCUS 5; HBFQTL5
Search EB-eye ENSG00000119866
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-1577, E-GEOD-7224, E-MEXP-433, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37
PC3
2
E-GEOD-5258, E-MEXP-2034
A549
2
E-GEOD-3202, E-GEOD-6013
BT474
2
E-MTAB-37, E-MEXP-440
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC2157
2
E-MTAB-37, E-MTAB-62
506 more value(s).


Cell type

studied in E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (62 experiments)

Factor Value U/D Experiments
CD8+ T cell
1
4
E-AFMX-5, E-GEOD-6740, E-TABM-145, E-MTAB-25, E-GEOD-19069 ... (5 experiments)
embryonic stem cell
3
E-MEXP-930, E-GEOD-2248, E-MEXP-2426
stromal cell
3
E-MEXP-2034, E-MEXP-1327, E-GEOD-1460
macrophage
2
E-GEOD-3982, E-GEOD-8286
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
134 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, ... (70 experiments)

Factor Value U/D Experiments
control
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-20295, E-GEOD-20602
prostate carcinoma
3
E-MTAB-62, E-MEXP-1327, E-MEXP-2034
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-MEXP-567, E-MTAB-62
lung adenocarcinoma
1
3
E-MTAB-62, E-GEOD-2514, E-MTAB-37, E-MEXP-231
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
207 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (25 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
AMP
1
E-MEXP-2285
estradiol
1
E-GEOD-20081
glucose
1
E-MEXP-941
granulocyte-colony stimulating factor
1
E-GEOD-7400
17beta-estradiol
4
1
E-GEOD-2292
39 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
1
E-GEOD-21521
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-22513, E-MEXP-1251, E-GEOD-19246, ... (12 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-GEOD-2666, E-MEXP-2283, E-MEXP-958, ... (6 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-MEXP-2340, E-GEOD-4006, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-22278, E-GEOD-10315, E-TABM-440, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (37 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-17204

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-GEOD-3485, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-43, E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-43, E-GEOD-1561, E-GEOD-4922

Processing time: 0.384 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM